CDKN2A and acute myeloid leukemia: Our in vitro data provide an appropriate explanation by demonstrating that Twist1-overexpressing AML cells are more vulnerable to the cytotoxicity of phase-specific cytarabine through suppression of cell cycle regulator p16.